COVID-19 and a Tale of Three Drugs: To Repurpose, or Not to Repurpose–That Was the Question
Viruses · 23.06.2025 · 17 (7) · 881
DOI: 10.3390/v17070881 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 23.06.2025. Verfasst von Chris R Triggle und 1 weiteren Autor:innen. Beteiligte Einrichtung: Weill Cornell Medicine-Qatar, Doha P.O. Box 24144, Qatar. Hauptthemen laut MEDLINE: Drug Repositioning, COVID-19 Drug Treatment, Antiviral Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: WCM-Q.
Abstract (Originalsprache)
On 11 March 2020, the World Health Organisation (WHO) declared a global pandemic caused by the SARS-CoV-2 coronavirus that earlier in February 2020 the WHO had named COVID-19 (coronavirus disease 2019). There were neither drugs nor vaccines that were known to be effective against the virus, stimulating an urgent worldwide search for treatments. An evaluation of existing drugs by ‘repurposing’ was initiated followed by a transition to de novo drug discovery. Repurposing of an already approved drug may accelerate the introduction of that drug into clinical use by circumventing early, including preclinical studies otherwise essential for a de novo drug and reducing development costs. Early in the pandemic three drugs were identified as repurposing candidates for the treatment of COVID-19: (i) hydroxychloroquine, an anti-malarial also used to treat rheumatoid arthritis and lupus; (ii) ivermectin, an antiparasitic approved for both human and veterinary use; (iii) remdesivir, an anti-viral originally developed to treat hepatitis C. The scientific evidence, both for and against the efficacy of these three drugs as treatments for COVID-19, vied with public demand and politicization as unqualified opinions clashed with evidence-based medicine. To quote Hippocrates, “There are in fact two things, science and opinion; the former begets knowledge, the latter ignorance”.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Weill Cornell Medicine-Qatar, Doha P.O. Box 24144, Qatar.
ORCID-Profile: Ross MacDonald
Förderung
- WCM-Q
Zitieren
APA
Triggle, C. R., & MacDonald, R. (2025). COVID-19 and a Tale of Three Drugs: To Repurpose, or Not to Repurpose–That Was the Question. Viruses, 17(7), 881. https://doi.org/10.3390/v17070881
Vancouver
Triggle CR, MacDonald R. COVID-19 and a Tale of Three Drugs: To Repurpose, or Not to Repurpose–That Was the Question. Viruses. 2025;17(7):881. doi:10.3390/v17070881
BibTeX
@article{Triggle2025,
author = {Triggle, Chris R and MacDonald, Ross},
title = {COVID-19 and a Tale of Three Drugs: To Repurpose, or Not to Repurpose–That Was the Question},
journal = {Viruses},
year = {2025},
volume = {17},
number = {7},
pages = {881},
doi = {10.3390/v17070881}
}
EUVIMED